NUTRALIFE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0001 USD | -66.67% |
|
-.--% | -50.00% |
Valuation
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 13.08 | 52.96 | 17.99 | 10.56 | 15.11 | 13.01 |
| Enterprise Value (EV) 1 | 14.84 | 52.79 | 17.78 | 12.56 | 18.26 | 16.01 |
| P/E ratio | -6.1 x | -2.01 x | -8.36 x | -2.12 x | -4.81 x | -2.18 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 58.1 x | 29.6 x | 4.85 x | 4.95 x | 12 x | 20.8 x |
| EV / Revenue | 65.9 x | 29.5 x | 4.79 x | 5.89 x | 14.5 x | 25.6 x |
| EV / EBITDA | -10.4 x | -2.61 x | -9.66 x | -3.84 x | -9.89 x | -3.67 x |
| EV / FCF | -102 x | 12.3 x | 1,140 x | -5.3 x | 31.4 x | 17.9 x |
| FCF Yield | -0.98% | 8.11% | 0.09% | -18.9% | 3.19% | 5.59% |
| Price to Book | -8.3 x | 81.4 x | 23.7 x | 6.65 x | 50.6 x | -18.5 x |
| Nbr of stocks (in thousands) | 34,419 | 80,249 | 90,605 | 140,847 | 159,039 | 168,698 |
| Reference price 2 | 0.3800 | 0.6600 | 0.1985 | 0.0750 | 0.0950 | 0.0771 |
| Announcement Date | 11/1/17 | 4/17/18 | 4/2/19 | 3/19/21 | 6/24/21 | 4/11/22 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net sales 1 | 0.2253 | 1.79 | 3.711 | 2.134 | 1.256 | 0.6266 |
| EBITDA 1 | -1.432 | -20.21 | -1.84 | -3.271 | -1.846 | -4.358 |
| EBIT 1 | -1.493 | -20.29 | -1.906 | -3.395 | -1.973 | -4.473 |
| Operating Margin | -662.57% | -1,133.39% | -51.36% | -159.14% | -157.12% | -713.77% |
| Earnings before Tax (EBT) 1 | -2.099 | -23.63 | -2.075 | -4.007 | -2.89 | -5.828 |
| Net income 1 | -2.099 | -23.63 | -2.075 | -4.007 | -2.89 | -5.828 |
| Net margin | -931.57% | -1,319.94% | -55.9% | -187.82% | -230.13% | -929.99% |
| EPS 2 | -0.0623 | -0.3290 | -0.0238 | -0.0354 | -0.0197 | -0.0354 |
| Free Cash Flow 1 | -0.1456 | 4.283 | 0.0156 | -2.371 | 0.582 | 0.8946 |
| FCF margin | -64.65% | 239.25% | 0.42% | -111.11% | 46.35% | 142.77% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 11/1/17 | 4/17/18 | 4/2/19 | 3/19/21 | 6/24/21 | 4/11/22 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 1.76 | - | - | 2 | 3.16 | 3.01 |
| Net Cash position 1 | - | 0.17 | 0.2 | - | - | - |
| Leverage (Debt/EBITDA) | -1.23 x | - | - | -0.6117 x | -1.71 x | -0.6899 x |
| Free Cash Flow 1 | -0.15 | 4.28 | 0.02 | -2.37 | 0.58 | 0.89 |
| ROE (net income / shareholders' equity) | 116% | 3,282% | -281% | -333% | -306% | 2,833% |
| ROA (Net income/ Total Assets) | -173% | -1,803% | -85.6% | -67.4% | -26.9% | -58.5% |
| Assets 1 | 1.21 | 1.31 | 2.424 | 5.945 | 10.75 | 9.963 |
| Book Value Per Share 2 | -0.0500 | 0.0100 | 0.0100 | 0.0100 | 0 | -0 |
| Cash Flow per Share 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capex 1 | 0.02 | 0.17 | 0.58 | 1.46 | - | - |
| Capex / Sales | 7.24% | 9.56% | 15.67% | 68.64% | - | - |
| Announcement Date | 11/1/17 | 4/17/18 | 4/2/19 | 3/19/21 | 6/24/21 | 4/11/22 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -50.00% | 18.06K | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- NLBS Stock
- Financials NutraLife BioSciences, Inc.
